Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28961356 | 0.84 | ALDH1A1 (0.48) | LMNATHRBMAPTKMT2AEPHX1 | |
| SCHEMBL3963418 | 0.77 | POLB (0.58) | LMNATHRBPOLBMAPTUSP30 | |
| SCHEMBL26651051 | 0.77 | PARP1 (0.47) | LMNATHRBPOLBMAPTUSP30 | |
| SCHEMBL26651044 | 0.77 | USP30 (0.48) | LMNATHRBPOLBMAPTUSP30 | |
| SCHEMBL16607990 | 0.77 | LMNA (0.58) | LMNAMAPTUSP30KMT2AEPHX1 | |
| SCHEMBL26170172 | 0.76 | PARP1 (0.48) | LMNATHRBPOLBMAPTUSP30 | |
| SCHEMBL26769374 | 0.76 | BACE1 (0.44) | LMNAMAPTMEN1KMT2A | |
| SCHEMBL28923421 | 0.76 | USP30 (0.56) | LMNATHRBPOLBMAPTUSP30 | |
| SCHEMBL30158356 | 0.74 | EED (0.45) | THRBPOLBMAPTMEN1KMT2A | |
| SCHEMBL26651061 | 0.74 | EED (0.45) | THRBPOLBMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | LMNA 304/4885THRB 2829/4885POLB 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.